HALAVEN

Reason for request

Clinical Benefit

Substantial

The actual benefit of HALAVEN is substantial.

Clinical Added Value

minor

HALAVEN provides a minor improvement in actual benefit (level IV) in the treatment of patients with metastatic or locally advanced breast cancer and who have seen disease progression after previous treatment with anthracycline and taxane, except for patients not able to receive these treatments.